Bellicum Pharmaceuticals Stock News

HOUSTON, May 27, 2020 -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that.

Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).

Bellicum’s three GoCAR™ programs remain on track Completed $15 million sale of manufacturing, office and laboratory facility to MD Anderson and entered into supply agreement.

Long term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic...

Gainers The Peck Company Holdings, Inc. (NASDAQ: PECK) shares climbed 68.5% to $4.50. Core Molding Technologies, Inc. (NYSE: CMT) gained 35.1% to $3.2429. TriState Capital...

M.D. Anderson has halted research and development activity on the Houston pharmaceutical firm's product candidates in response to the COVID-19 pandemic.

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) was the recipient of a significant decline in short interest in the month of March. As of March 31st, there was short interest totalling 417,700 shares, a de

Purchase price of $15 million from sale of manufacturing, office and laboratory facility Current and future GoCAR™ product candidates to be manufactured by MD Anderson.